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Background: Lymphatic filariasis (LF) is a major public health problem in the Pacific. As the global prevalence of
infection was not known in New Caledonia (NC), a serosurvey study was conducted by determining the prevalence
of circulating filarial antigens, as recommended by the World Health Organization.
Findings: A cross sectional study on a 2 degree stratified sample was carried out from June to November 2013.
Inclusion criteria were: individuals aged 2 to 80 y/o, who had been hospitalized or sought medical care for a
non-infectious cause and who had been living in NC for more than 6 months. LF antigenic detection was performed
using the immunocromatographic BinaxNOW filariasis card test (ICT).
Among the 1,035 individuals tested, 7 were antigenic. The overall LF antigenic prevalence was 0.62% (CI 95% [0.60-0.63]).
All patients were unrelated to each other; none of them presented clinical symptoms of LF.
Four of the 7 ICT positive patients reported having travelled to LF endemic areas, 2 patients had never traveled outside
NC and the last one had only traveled in non-endemic areas.
For the 7 ICT positive patients, the research of microfilariae in blood smears and filarial DNA by PCR was negative.
Conclusion: The prevalence of filarial antigenemia in NC is less than 1%, the threshold that defines the filarial endemic
areas for WHO. Nevertheless, as two patients who had never travelled outside NC and one who had only travelled to
non-endemic areas were antigenic, we cannot conclude that NC is totally free of LF.
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Lymphatic Filariasis (LF) is transmitted by mosquitoes
and caused by three species of nematodes but only
Wuchereria bancrofti is found in the Pacific area [1-3].
Filariasis, is common in many parts of the tropics and
subtropics, including Pacific island countries and terri-
tories (PICTs). This neglected tropical disease is a major
cause of disability, social stigmatization and reduced
economic life opportunities [4,5]. In 1997, the World
Health Organization (WHO) declared LF to be one of six
potentially eradicable diseases, and the Global Programme
to Eliminate Lymphatic Filariasis (GPELF) was then
established with the goal of the “elimination of LF as a
public health problem by the year 2020 [6,7]”.* Correspondence: maguy.daures@gmail.com
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unless otherwise stated.New Caledonia (NC) is a French Territory located in the
Southwest Pacific Ocean. It is one of the 22 PICTs com-
prising 250.000 inhabitants (40.3% Melanesian, 34.6%
European, 9.3 mixed-race, 8.7% Wallisian, 2.0% Tahitian, a
few Asian and Vanuatuan, and 5.1% indeterminate).
Historically, the levels of filariasis in the Pacific area
have been some of the highest in the world [3]. In 1999,
the Pacific Programme to Eliminate Lymphatic Filariasis
(PacELF) was created [8] and most of the PICTs, but not
NC, conducted initial surveys to map the extent of LF.
As elephantiasis was not being diagnosed in NC and
Aedes polynesiensis, the main vector of LF in the Pacific
region was not present [9], it was assumed that the over-
all prevalence of LF would be low. Nevertheless, since
French Polynesia (FP) is still a high endemic area for LF
[10] and this ethnic group accounts for 2.0% of the NC
population with routine travel exchanges between the
two countries, we cannot exclude the possibility that LF
is endemic in NC, especially in some remote areas suchThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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New Caledonia, where LF cases have been reported in
the past (Canala, Pouebo, Ouega) [11,12].
In order to evaluate NC’s status in regards to LF, we
conducted a serosurvey study by determining the preva-
lence of circulating filarial antigens (CFA) using immu-
nochromatographic card tests (ICT), as recommended
by the WHO [13].
Methods
The serosurvey study was conducted from June to
November 2013. A cross sectional study on a 2 degree
stratified sample was implemented. Inclusion criteria were:
individuals aged 2 to 80 y/o, who had been hospitalized or
had sought medical care for a non-infectious cause
(temperature below 37.5°C) and who had been living in
NC from more than 6 months.
Ethical approval was obtained by the People Protection
Committee South-west and Overseas III, Bordeaux, France
under reference 13.269. Informed written consent was ob-
tained from all participants for medical interview and
blood samples.Figure 1 Distribution of individuals included, prevalence of antigenemiThe sample size was calculated for a cross sectional
study with consideration of the sample plan (design
effect) [14,15]. A total of 1,321 individuals were to be
included in the study for a seroprevalence precision
of +/− 4% (a refusal rate of 10% was planned).
Sampling design: NC was first stratified in 5 areas
[Noumea has 39.7% inhabitants of NC, the greater Noumea
area (26.9%), East Coast (12.9%), West Coast (13.4%) and
Loyalty Islands (7.1%)]. At the first stage, a randomized
selection of medical centers and GPs was made. At the
second stage, eligible individuals were included in the
study by systematic sampling.
Data on socio-demographic characteristics and his-
tory of travel were collected using a standardized ques-
tionnaire. A blood sample was collected by venous
puncture at the end of the interview. For children
under the age of 10y/o, antigenic detection was per-
formed only on blood samples collected for other
reasons.
After collection, samples were stored and then shipped
at −20°C to the Louis Malarde Institute in Tahiti (FP)
where they were stored at – 20°C until processing.a in the different NC areas and location of the ICT positive patients.
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nocromatographic BinaxNOW filariasis test (Alere North
America, Orlando, USA) (Inverness Medical) following
the manufacturer’s instruction. In order to avoid false
positive reactions the results were recorded 10 minutes
after specimen application [16].
After antigenic testing results were obtained, all antigen-
positive individuals were contacted and examined by a
medical practitioner from the New Caledonia Health
Department in order to detect any clinical symptoms
of LF. A second blood sample was taken for micro-
scopic and molecular filarial detection. For molecular
detection of filarial DNA [17], whole blood was spotted
on filter paper and sent to the Louis Malarde Institute
in Tahiti FP for individual molecular detection by poly-
merase chain reaction, as previously described [18].
The data were analyzed using STATA 12.1 software.
Data were adjusted by sex, estimates and confidence in-
tervals (CI) were calculated using the “survey” command
to consider the sampling plan. The prevalence and 95%
CI of filariasis standardized by age was estimated based
on the WHO world reference population.
Findings
A total of 1035 individuals were included in the study.
Melanesians were over-represented (48.3%) and Europeans
underrepresented (22.9%) in the sample compared to the
general population (p < 0.0001).
The overall LF antigenic prevalence (after considering
the sample plan) was 0.62% (CI 95% [0.60-0.63]). TheTable 1 Clinical and laboratory findings for the 7 antigenemi
Patients 1 2 3
age 64 62 3
sex M F M
Community Melanesian European M
Birthplace NC NC N
NC arrival date
Laboratory results
ICT Positive Positive P
Microfilaremia Negative Negative N
LF PCR Negative Negative N
Lived/worked in LF area known in NC* Yes Yes Y
Travels in LF endemic countries
Travel 1 Malaisia V
Year 1988 2
Travel 2 Vanuatu (x3)
Year 2004, 2005, 2007
Travel 3
Year
*Ouvea Island, Koumac, Canala, Ouegoa, Pouebo. Never left the territory. Visited onICT filariasis test was positive for 7 patients. Prevalence
of antigenemia in the different NC areas and locations
of the ICT positive patients is shown in Figure 1.
For the 7 ICT positive, all the data recorded through
the medical questionnaire and their laboratory data are
given in Table 1. The median age of those patients was
35 y/o (ranging from 28 to 64 y/o), the sex ratio (F/M)
was 1.33, 5 lived in Noumea, 1 in Belep Islands and 1 in
a village on the West Coast. Two were Melanesians and
five were Europeans, none of them were from the Tahi-
tian population living in NC. All patients were unrelated
to each other; none of them showed any clinical symp-
toms of LF.
Four of the 7 ICT positive patients reported having trav-
elled in the past in an LF endemic country (Vanuatu, FP,
Indonesia, Viet Nam, Malaysia and Sri Lanka), 2 had never
traveled outside NC to an LF endemic country [19].
For the 7 ICT positive patients tested for live microfil-
ariae and filarial DNA were negative.
Each ICT positive patient received treatment consist-
ing of a single dose of albendazole (400 mg) and diethyl
carbamazine (400 mg).
Discussion
According to WHO, non-endemic areas for LF are those
areas where surveys have shown an infection rate of less
than 1% [13]. The overall LF prevalence estimated in NC
was 0.62% (CI 95% [0.60-0.63]), which allows us to clas-
sify NC as a non-endemic PICTs for LF, according to
WHO criteria.c patients
4 5 6 7
4 28 35 31 47
F F M F
etis European Melanesian Metis European
C NC NC NC France
1991
ositive Positive Positive Positive Positive
egative Negative Negative Negative Negative
egative Negative Negative Negative Negative
es No Yes No Yes
anuatu Vanuatu Vanuatu (x3)
011 1994 1994, 1998, 2010
Indonesia French Polynesia (x10)
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tested positive for LF antigenemia.
Patients 2, 3, 6 and 7 reported having travelled in the past
to LF endemic PICTs or countries (principally Vanuatu and
FP) where they may have been contaminated. Vanuatu was
one of the first PICTs to initiate the GPELF; after two
MDA campaigns LF antigenic prevalence in sentinel sites
was 8% in 2002 [20]. FP is another PICTs that has a high
LF endemic area. Despite eight rounds of MDA from 2000
to 2007, the overall prevalence was 11.3% in 2008 [10]. The
main drawback of LF antigenic detection is that it can re-
main positive years after the infection because adult LF
worms, once dead, release substances detected by the CFA
test [21].
Patients 1 and 5 had never left NC and patient 4 had
only travelled in non-endemic areas. For them it is not
possible to say whether or not they were infected in NC
or if the positive result of the antigenemia was a false
positive. The occurrence of false positive results in our
study is to be considered because the predictive positive
value of a test decreases when the prevalence of the dis-
ease in the studied population is low.
Patient 5 was born and had lived 29 years on Ouvea Is-
land and may have been contaminated during those years.
A study conducted in 1996 in this island showed that 3.7%
of the 382 adults tested were microfilaremic [11].
Patients 1,2,3,5,7 had worked or lived in the northern
part of NC (Koumac, Ouegoa, Pouebo) or on East Coast
(Canala), where filariasis cases have been reported ac-
cording to a study conducted in 1979–1980 [12].
The seven antigenemic patients were asymptomatic,
tested negative for microfilairemia and filarial DNA, and
they received preventive treatment, then, no follow
protocol has been implemented.
Conclusion
In view of the results, we conclude that the LF preva-
lence in NC is less than 1%, so we assume that LF is not
a public health concern in NC and that there is no need
to set up the GPELF. Nevertheless, as the overall popula-
tion has not been tested and as three patients had never
been exposed in endemic areas, we cannot conclude that
NC is totally free of LF, especially in some very remotes
areas. To our knowledge, Aedes vigilax is the potential
vector of LF in NC [12], Ae. polynesiensis, the main vec-
tor of LF in the Pacific is not present in NC, suggesting
that the potential for filariasis emergence is low in this
country.
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